PVLA

Insider Trades

Name	Value	Action	Price	Current Price
Goin KathleenChief Operating Officer $371k3.4k shares SellMay 20, 2026 $110.35 --
Goin KathleenChief Operating Officer $99k891 shares SellMay 20, 2026 $111.30 --
Goin KathleenChief Operating Officer $5.4k48 shares SellMay 20, 2026 $111.90 --
Goin KathleenChief Operating Officer $191k1.5k shares SellApr 15, 2026 $127.13 --
Goin KathleenChief Operating Officer $189k1.5k shares SellApr 15, 2026 $125.96 --
Goin KathleenChief Operating Officer $83k639 shares SellApr 15, 2026 $129.17 --

News

seekingalpha.comPalvella Therapeutics, Inc. (PVLA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcriptseekingalpha.comJun 9

seekingalpha.comPalvella Therapeutics: Qtorin Continues Making Progress, So I Remain Bullishseekingalpha.comJun 5

globenewswire.comPalvella Therapeutics Announces Completion of FDA Pre-NDA Meeting for QTORIN™ Rapamycin in Microcystic Lymphatic Malformationsglobenewswire.comJun 3

globenewswire.comPalvella Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026globenewswire.comJun 2

globenewswire.comPalvella Therapeutics Strengthens QTORIN™ Pitavastatin Intellectual Property with Yale-Licensed U.S. Patent Providing Protection into 2043globenewswire.comMay 27

Trade PVLA

About Palvella Therapeutics, Inc.

Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions. Central to its pipeline is QTORIN 3.9% rapamycin anhydrous gel (referred to as QTORIN rapamycin), which is currently undergoing Phase 3 clinical trials for microcystic lymphatic malformations. Additionally, this drug is in Phase 2 evaluation for treating cutaneous venous malformations. Beyond these specific indications, Palvella is also advancing QTORIN rapamycin for the treatment of other dermatological diseases driven by the mTOR pathway. The company's headquarters are situated in Wayne, Pennsylvania.

CEO: Wesley H. Kaupinen
IPO Date: Jan 2, 2015

Market Data

Open: $116.37
High: $116.60
Low: $110.96
Volume: 296.7K
Avg Volume: 246.2K
52W High: $151.18
52W Low: $20.35

Valuation

Market Cap: $1.3B
Enterprise Value: $1.1B
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-25M
Revenue: $0
Net Income: $-42M
Cash: $58M
Debt: $633k

Events

EarningsAug 13

EPS est. -1.16